Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

SGLT-2 inhibitors in development for type 2 diabetes treatment.

Bhartia M, Tahrani AA, Barnett AH.

Rev Diabet Stud. 2011 Fall;8(3):348-54. doi: 10.1900/RDS.2011.8.348. Epub 2011 Nov 10. Review.

2.

[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].

Albarrán OG, Ampudia-Blasco FJ.

Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. doi: 10.1016/S0025-7753(13)70062-9. Review. Spanish.

PMID:
24444523
3.

Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.

Vivian EM.

Am J Health Syst Pharm. 2015 Mar 1;72(5):361-72. doi: 10.2146/ajhp140168. Review.

PMID:
25694411
4.

[Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].

Sanz-Serra P, Pedro-Botet J, Flores-Le Roux JA, Benaiges D, Chillarón JJ.

Clin Investig Arterioscler. 2015 Jul-Aug;27(4):205-11. doi: 10.1016/j.arteri.2014.11.001. Epub 2015 Jan 31. Review. Spanish.

PMID:
25648671
5.

Empagliflozin for the treatment of Type 2 diabetes.

Gangadharan Komala M, Mather A.

Expert Rev Clin Pharmacol. 2014 May;7(3):271-9. doi: 10.1586/17512433.2014.908703. Epub 2014 Apr 9. Review.

PMID:
24716752
6.

The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.

Lajara R.

Expert Opin Pharmacother. 2014 Dec;15(17):2565-85. doi: 10.1517/14656566.2014.968551. Epub 2014 Oct 15. Review.

PMID:
25316597
7.

The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.

Whalen K, Miller S, Onge ES.

Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16. Review.

PMID:
25891804
8.

SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.

Cuypers J, Mathieu C, Benhalima K.

Acta Clin Belg. 2013 Jul-Aug;68(4):287-93. Review.

PMID:
24455799
9.

The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.

Riser Taylor S, Harris KB.

Pharmacotherapy. 2013 Sep;33(9):984-99. doi: 10.1002/phar.1303. Epub 2013 Jun 6. Review.

PMID:
23744749
10.

[Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].

Rosak C, Forst T.

MMW Fortschr Med. 2012 Dec 17;154 Suppl 4:95-101. Review. German.

PMID:
23326927
11.

SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus.

Nathan KT, Ahmed-Sarwar N, Werner P.

Consult Pharm. 2016 May;31(5):251-60. doi: 10.4140/TCP.n.2016.260. Review.

PMID:
27178654
12.

Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.

Miller K, Miller EM.

J Fam Pract. 2015 Dec;64(12 Suppl):S54-8. Review.

PMID:
26845015
13.

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.

Neumiller JJ, White JR Jr, Campbell RK.

Drugs. 2010 Mar 5;70(4):377-85. doi: 10.2165/11318680-000000000-00000. Review.

PMID:
20205482
14.

Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.

Demaris KM, White JR.

Drugs Today (Barc). 2013 May;49(5):289-301. doi: 10.1358/dot.2013.49.5.1964714.

PMID:
23724409
15.

Dapagliflozin: a review on efficacy, clinical effectiveness and safety.

Paisley AN, Yadav R, Younis N, Rao-Balakrishna P, Soran H.

Expert Opin Investig Drugs. 2013 Jan;22(1):131-40. doi: 10.1517/13543784.2013.740009. Epub 2012 Nov 6. Review. Erratum in: Expert Opin Investig Drugs. 2013 Jul;22(7):939. Paisley, Angela J [corrected to Paisley, Angela N].

PMID:
23127205
16.

Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.

Davis PN, Ndefo UA, Oliver A.

J Pharm Pract. 2016 Apr;29(2):165-71. doi: 10.1177/0897190014566308. Epub 2015 Jan 21. Review.

PMID:
25609661
17.

Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.

Dailey GE.

Drugs Today (Barc). 2015 Sep;51(9):519-35. doi: 10.1358/dot.2015.51.9.2368554. Review.

PMID:
26488032
18.

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.

Santos LL, Lima FJC, Sousa-Rodrigues CF, Barbosa FT.

Rev Assoc Med Bras (1992). 2017 Jul;63(7):636-641. doi: 10.1590/1806-9282.63.07.636. Review.

19.

Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.

Ghosh A, Gupta R, Misra A.

J Diabetes. 2016 Sep;8(5):738-9. doi: 10.1111/1753-0407.12411. Epub 2016 Jul 1. No abstract available.

PMID:
27085074
20.

Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.

Mende CW.

Curr Med Res Opin. 2017 Mar;33(3):541-551. doi: 10.1080/03007995.2016.1271779. Epub 2017 Jan 4. Review.

PMID:
27977314

Supplemental Content

Support Center